Report Summary 1. Report Industry Investment Rating The report does not explicitly mention the industry investment rating. 2. Core Views of the Report - "Anti - involution" may be Supply - side Reform 2.0, potentially driving a significant rebound in PPI and impacting the bond market [2]. - The stock market is rising steadily, with a notable increase in risk appetite. This may attract funds into the stock market, putting pressure on the bond market [2]. - China's export resilience is prominent. There is a possibility of a further reduction in US tariffs on China, which could promote export growth [2]. - The commencement of the Yarlung Zangbo River downstream hydropower project may boost infrastructure investment growth and drive up related stock prices [2]. - The bond market is expected to fluctuate narrowly in the short term. Attention should be paid to the progress of "anti - involution". The report recommends long - duration sinking of urban investment bonds, capital bonds, and insurance sub - bonds, and suggests paying attention to investment opportunities in certain capital bonds and Hong Kong - listed bank stocks [2]. 3. Summary by Related Aspects Macroeconomic Policy Impact - In 2015, supply - side reform and shantytown renovation promoted a significant rebound in PPI and nominal GDP growth, causing the bond market to decline. In 2025, "anti - involution" has become the focus of economic policy and may have a similar impact [2]. Stock and Bond Market Relationship - Since the Spring Festival in 2025, the stock market has been rising steadily, ending the negative economic cycle from 2022 - 2024. The wealth effect of the stock market promotes consumption, and the inflow of funds into the stock market may put pressure on the bond market [2]. Export Situation - China's total export value has grown rapidly in the past year. The resilience of exports is not only due to "rush - to - export" but also reflects the global competitiveness of many industries. A reduction in US tariffs on China could further boost exports [2]. Infrastructure Investment - The Yarlung Zangbo River downstream hydropower project, with a total investment of about 1.2 trillion yuan, may drive the stabilization of infrastructure investment growth and the rise of related stocks [2]. Bond Market Outlook - The bond market's trading volume is overly concentrated in ultra - long - term interest - rate bonds. If the "anti - involution" efforts are strong, it may lead to the collapse of the ultra - long - term bond concentration and a 10 - 20BP adjustment in the bond market. The 10 - year Treasury yield may need a new round of interest rate cuts to reach a new low. In the short term, the bond market will fluctuate narrowly, and attention should be paid to the progress of "anti - involution" [2].

Investment Rating - The report assigns a "Buy" rating for Alibaba Group, marking its first coverage of the company [5][7]. Core Views - The report emphasizes Alibaba's strategic focus on e-commerce and cloud services, with a clear management structure aimed at enhancing operational efficiency and market competitiveness [6][20]. - It highlights the expected recovery of growth momentum in Alibaba's core e-commerce business, driven by improved monetization strategies and a competitive edge in product offerings [36][42]. - The cloud business is positioned as a leader in the industry, benefiting from AI integration and a strong market presence, which is anticipated to drive revenue growth [53][66]. Summary by Sections 1. Strategic Focus on Cloud and E-commerce - Alibaba has transitioned from a diversified governance model to a strategic focus on core areas, particularly e-commerce and cloud services, with significant investments in AI infrastructure [14][20]. - The management structure has been streamlined to enhance focus on these two key business segments, with dedicated leadership for each [15][19]. 2. Core E-commerce Business Recovery - The e-commerce sector is experiencing a slowdown in competition, allowing Alibaba's Taobao and Tmall platforms to regain market share, achieving a GMV share of 48.4% during the 2025 618 shopping festival [39][40]. - The company is implementing strategies such as commission rebates and AI enhancements to support merchant growth and improve user engagement [46][48]. 3. Cloud Business Leadership - Alibaba Cloud maintains a leading position in the public cloud market, with a market share of approximately 25% in both IaaS and PaaS segments [62][65]. - The cloud division is expected to benefit from increased demand for AI services, with revenue growth projected at 23.1% to 25.0% from FY2026 to FY2028 [8][30]. 4. Financial Projections - The report forecasts Alibaba's revenue and net profit growth, with expected revenues of RMB 1,011,541.9 million in 2026 and net profits of RMB 145,092.4 million, reflecting a year-on-year growth rate of 11.5% [5][6]. - The projected P/E ratios for 2025 are 13, 12, and 11 for the following years, indicating a favorable valuation compared to peers in the e-commerce and cloud sectors [7][8].

Investment Rating - The investment rating for the company is upgraded to "Buy" due to the planned acquisition of thermal power assets, indicating a positive outlook on the company's configuration value [4]. Core Views - The report highlights the company's intention to acquire 100% equity of Nantai Lake Technology, which focuses on coal-fired combined heat and power generation, biomass, and solid waste disposal. The acquisition is expected to enhance the company's profitability and asset scale [5]. - The estimated value of the acquisition is approximately 1.457 billion RMB, based on a negotiated price after accounting for a cash dividend of 70 million RMB to be paid before the transfer [5]. - The company plans to maintain a cash dividend payout of no less than 40% of the net profit attributable to shareholders for the years 2024-2026, with a projected dividend payout ratio of 45.32% for 2024 [5]. Financial Summary - The company's revenue for 2023 is projected at 44.327 billion RMB, with a year-on-year decline of 19.70%. The revenue is expected to recover slightly in 2024 with a growth rate of 0.86% [4]. - The net profit attributable to shareholders is forecasted to be 1.059 billion RMB in 2023, decreasing by 0.31% year-on-year, and is expected to decline further to 739 million RMB in 2024 [4]. - The earnings per share (EPS) for 2023 is estimated at 1.90 RMB, with a projected decrease to 1.32 RMB in 2024 [4]. - The company's return on equity (ROE) is expected to decrease from 20.52% in 2023 to 13.40% in 2024, reflecting the impact of the acquisition and market conditions [4].

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - Increased marketing investment is expected to gradually catalyze performance growth through sports resources [5] - The company has become a partner of the Chinese Olympic Committee, which is anticipated to enhance its product matrix and brand image [7] - The signing of player Yang Hanshen, who was selected in the first round of the NBA draft, is expected to boost the popularity of the company's basketball-related products [7] - The company is focusing on a "single brand, multiple categories, and multiple channels" development strategy, which is expected to drive long-term growth [7] Financial Summary - Revenue projections for the company are as follows: - 2023: 27,598.49 million RMB - 2024: 28,675.64 million RMB - 2025E: 29,026.63 million RMB - 2026E: 30,765.67 million RMB - 2027E: 32,844.70 million RMB - The expected growth rates for revenue are 6.96% in 2023, 3.90% in 2024, 1.22% in 2025, 5.99% in 2026, and 6.76% in 2027 [6] - Projected net profit attributable to the parent company is as follows: - 2023: 3,186.91 million RMB - 2024: 3,012.92 million RMB - 2025E: 2,644.93 million RMB - 2026E: 2,846.01 million RMB - 2027E: 3,103.86 million RMB - The expected net profit growth rates are -21.58% in 2023, -5.46% in 2024, -12.21% in 2025, 7.60% in 2026, and 9.06% in 2027 [6][8]

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The major shareholder's increase in holdings demonstrates confidence and reaffirms the company's cash flow value [5] - The company has a significant cash flow potential, with an average annual distributable cash flow of 750 million RMB over the past five years, suggesting a reasonable market value exceeding 10 billion RMB under a 7% discount rate [7] - The company's short-term performance is influenced by rainfall, but the overall value remains stable due to consistent cash flow and debt repayment [7] Financial Summary - The company's market capitalization is approximately 7,037.61 million RMB [3] - The company's total assets are projected to be 15,563 million RMB in 2024, decreasing to 14,705 million RMB by 2027 [8] - The projected revenue for 2025 is 2,423 million RMB, with a year-on-year growth rate of 25.34% [6] - The projected net profit attributable to shareholders for 2025 is 413 million RMB, with a significant year-on-year growth rate of 89.41% [6] - The earnings per share (EPS) for 2025 is estimated at 0.97 RMB, with a price-to-earnings (P/E) ratio of 17.03 [6][8]

Economic Overview - In the first half of 2025, China's economy demonstrated strong resilience with a GDP growth of 5.3% year-on-year, supported by consumption contributing 52.3% to economic growth [2][7][8] - The second quarter GDP growth was 5.2% year-on-year and 1.1% quarter-on-quarter, indicating a steady progress in economic performance [2][7] - The GDP deflator index has been negative for nine consecutive quarters, with a value of -1.0% in Q2 2025, while CPI turned positive for the first time in four months at +0.1% in June [2][7][8] Pharmaceutical Sector China Biologic Products (01177.HK) - The company announced a $500 million acquisition of 95.09% of Shanghai Lixin Pharmaceutical, which will enhance its core competitiveness in the oncology field through Lixin's differentiated dual-antibody and ADC technology platforms [10][11][13] - The acquisition is expected to significantly boost the company's capabilities in developing innovative drugs, with several promising candidates in clinical trials [12][13] Sinovac Biotech (688136.SH) - The company has established multiple leading technology platforms for innovative drug development, focusing on oncology and degenerative diseases, which are expected to enhance its valuation [15][16] - The innovative pipeline includes promising candidates that are anticipated to provide new valuation flexibility for the company [17][18] Precision Manufacturing Sector Easy Precision (836221.BJ) - The company reported a revenue of 80 million yuan and a net profit of 15.04 million yuan in Q1 2025, with a focus on precision metal components for the automotive industry [20][21] - Easy Precision is expanding its product line through strategic partnerships and is set to launch a third-generation welding ring production line in 2025, enhancing its market competitiveness [21][22] - The company plans to acquire a 51% stake in Tongyihe to enhance its precision stamping capabilities and drive the localization of harmonic reducer components [23][25]

Investment Rating - The industry investment rating is "Positive" (maintained) [4] Core Viewpoints - In June, the total retail sales of consumer goods increased by 4.8% year-on-year, reaching 42,287 billion yuan. Excluding automobiles, the total retail sales were 37,649 billion yuan, also up by 4.8% year-on-year [5][6] - The growth rate of retail sales in essential consumer goods remains stable, with significant increases in categories such as grain and oil food (+8.7%) and daily necessities (+7.8%). However, beverages (-4.4%) and tobacco and alcohol (-0.7%) saw declines [16][29] - In the optional consumption category, jewelry (+6.1%) and communication equipment (+13.9%) showed strong growth, while cosmetics (-2.3%) and clothing and footwear (+1.9%) had modest increases [26][32] - Notably, retail sales in the home appliance and furniture categories grew significantly, with furniture sales up by 28.7% and home appliances by 32.4% [34][36] Summary by Sections Overall Data - The total retail sales of consumer goods in June reached 42,287 billion yuan, with a year-on-year growth of 4.8%. Urban and rural retail sales were 36,559 billion yuan and 5,728 billion yuan, respectively, with growth rates of 4.8% and 4.5% [5][6] Consumption Types - Retail sales in essential goods showed robust growth, while optional goods had mixed results. The total retail sales for limited enterprises in June were 18,327 billion yuan, with a year-on-year increase of 5.0% [9][12] - The retail sales for essential goods categories included grain and oil food (+8.7%), daily necessities (+7.8%), while beverages (-4.4%) and tobacco and alcohol (-0.7%) declined [16][29] - In optional consumption, jewelry and communication equipment categories performed well, with growth rates of 6.1% and 13.9%, respectively [26][32] - The home appliance and furniture sectors saw remarkable growth, with furniture sales increasing by 28.7% and home appliances by 32.4% [34][36]

Investment Rating - The investment rating for the power equipment industry is "Positive" (maintained) [4] Core Viewpoints - The thermal power installed capacity has seen a significant year-on-year increase, with a delivery peak expected this year. In the first five months of this year, China added 17.55 million kilowatts of thermal power capacity, a substantial increase of approximately 45% compared to the same period last year [4] - The approval of coal power projects is expected to maintain a high level, with projections indicating that the approved capacity for coal power will exceed 80 GW for the year [4] - The growth in load demand is anticipated to outpace electricity consumption growth, driven by the increasing electricity demand from the tertiary sector and urban residents [4] - The need for traditional power sources like coal and nuclear power will persist due to the instability of renewable energy sources [4] - The demand for coal power replacement and upgrades is expected to continue expanding, with the implementation of the "New Generation Coal Power Upgrade Special Action Implementation Plan (2025-2027)" [4] - Pumped storage approvals are increasing, with the cumulative installed capacity expected to exceed 62 GW by 2025 and 120 GW by 2030 [4] - The total orders for pumped storage turbines are projected to reach approximately 150 billion yuan, with companies like Harbin Electric and Dongfang Electric expected to maintain high growth rates in their water power orders [4] Summary by Sections Section: Industry Performance - The coal power approval volume remains high, with significant increases in installed capacity expected in the coming years [4] Section: Investment Analysis - The sustained high approval volume for coal power and the increasing peak load demand indicate a long-term underestimated demand for coal power [4] - Companies such as Harbin Electric, Dongfang Electric (A+H), and Shanghai Electric are recommended for investment opportunities [4]

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The value of the company's innovative drug platform is gradually becoming apparent, with multiple leading technology platforms established, focusing on oncology, immunology, and degenerative diseases, indicating potential for revaluation [5][6] - The innovative pipeline provides expectations for international expansion, granting the company new valuation flexibility [6] Summary by Relevant Sections Market Performance - Closing price as of July 16, 2025, is 49.30 CNY, with a total market capitalization of 9,921.98 million CNY [3] Earnings Forecast and Valuation - Projected revenues for 2025-2027 are 1,684 million CNY, 2,071 million CNY, and 2,650 million CNY, respectively, with year-on-year growth rates of 19.68%, 22.98%, and 27.96% [7] - Expected net profit for the same period is 107 million CNY, 207 million CNY, and 346 million CNY, with significant year-on-year growth rates [7] - Price-to-earnings ratios (P/E) for 2025-2027 are projected at 93.02, 47.97, and 28.69, respectively [9] Innovative Pipeline - The company has developed several innovative drugs targeting significant medical needs, including GB18 for cancer cachexia, GB12 for atopic dermatitis, and GB20/GB24 for inflammatory bowel disease, all showing promising clinical progress [8][21][35] - GB18, targeting GDF15, has received IND approval in both China and the US, with a favorable competitive landscape and high clinical success probability [21][30] - GB20 and GB24, targeting TL1A, are positioned to address the growing market for inflammatory bowel disease, with significant patient numbers projected [35][39] Investment Logic - The company is expected to maintain high growth rates in overseas sales, particularly with the commercialization of key products in the EU and emerging markets [11] - The innovative drug development pipeline is progressing positively, with potential for significant valuation increases through successful business development (BD) transactions [11][19]

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [5] Core Views - The company is focusing on expanding its customer base in the field of air suspension and enhancing its precision stamping technology to promote the localization of reducer flexible wheels [5] - In Q1 2025, the company achieved revenue of 80 million yuan and a net profit attributable to shareholders of 15.04 million yuan [6] - The company has established itself as a supplier for well-known automotive parts manufacturers, including Tyco Electronics and Bosch [6] - The company signed a strategic cooperation agreement with Konghui Technology to broaden its product line and is expected to achieve mass production of the third-generation welding ring line in 2025 [6][9] - The company plans to acquire 51% of Tongyihe Precision Technology to enhance its development and manufacturing capabilities in precision stamping [6][9] - The establishment of a joint venture in Slovenia aims to enhance overseas layout and local supply capabilities [6][9] Financial Summary - The company forecasts revenue growth from 276 million yuan in 2023 to 609 million yuan in 2027, with a compound annual growth rate (CAGR) of approximately 22.91% [8] - The net profit attributable to shareholders is projected to increase from 52 million yuan in 2023 to 100 million yuan in 2027, reflecting a CAGR of 25.37% [8] - The earnings per share (EPS) is expected to rise from 0.44 yuan in 2023 to 0.86 yuan in 2027 [8] - The company maintains a healthy return on equity (ROE), projected to reach 23.54% by 2027 [8]